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Abstract
Background. This is a report on the clinical results of intra-arterial adjuvant chemotherapy in the prevention of liver
metastasis following curative resection of biliary tract cancer. Methods. Nineteen patients of advanced biliary tract
underwent a pathologically radical operation between 2001 and 2006 (8 M and 11 F; mean age 66.2 years). Intra-arterial
adjuvant chemotherapy with CDDP and 5-FU was performed selectively for 9 patients. The control group comprised 10
patients. Age, gender, staging of the disease, resection of the portal vein, postoperative radiotherapy, histological liver
invasion as demographics and clinical characteristics were compared between the two groups. Results. Demographics and
clinical characteristics were similar in the two groups. Liver metastasis occurred in 4 of 9 patients (44.4%) in the
chemotherapy group and in 5 of 10 patients (50%) in the control group. There was no difference in the rate of liver
metastasis between the two groups. The median survival term was 23.3 months for 9 patients who underwent the intra-
arterial adjuvant chemotherapy, whereas the median survival term for 10 patients who were curatively resected without
intra-arterial adjuvant chemotherapy was 21.7 months. The median survival term was statistically similar in both groups.
Furthermore, in the recurrence-free survival, there was no major difference between the chemotherapy and control groups
statistically. Conclusions. In the patients with advanced biliary tract cancer who underwent the curative operation, the intra-
arterial adjuvant chemotherapy could not suppress the rate of liver metastasis nor improve cumulative survival.
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Introduction
In addition to the difficulty of early biliary tract cancer
diagnosis, even if we could perform a radical opera-
tion for patients of biliary tract cancer, patients cannot
be guaranteed long-term survival.
In the present conditions, histological curative
operation and pertinent chemotherapy in the preven-
tion of early recurrence is important in improving the
prognosis of biliary tract cancer patients. This is a
report on the clinical results of intra-arterial adjuvant
chemotherapy (in the prevention of liver metastasis)
with CDDP and 5-FU performed on patients with
biliary tract cancer who underwent a radical opera-
tion.
Methods
Of 19 patients (8 M and 11 F; mean age 66.2 years;
range 4580 years) with advanced biliary tract cancer
who underwent a radical operation between October
2001 and September 2006, 3 had cancer of the
Ampulla of Vater, 8 extrahepatic bile duct cancer,
and 8 gallbladder cancer.
Diagnosis was confirmed in all patients by histolo-
gical examination. The clinicopathological features of
patients are given in Tables I and II. We performed
post-surgery serial observation, i.e. conducting blood
examinations, (dynamic) contrast-enhanced CT ima-
ging, and ultrasonography on patients every 4
months. All data were analyzed in accordance with
the latest versions of the Japanese classification of
Biliary Tract Carcinoma [1].
Lymph node dissection is defined as the D factor,
as follows: D0: no dissection of group 1 lymph nodes;
D1: dissection of group 1 lymph nodes alone; D2:
dissection of groups 1 and 2 lymph nodes; and, D3:
dissection of groups 1, 2 and 3 lymph nodes.
According to the JCS, 9 patients had Stage III biliary
tract cancer. The other 10 patients were diagnosed as
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Stage IV biliary tract cancer using the Japanese
Classification of Biliary Tract Carcinoma. Operative
procedures in the 19 patients are given in Tables I and
II. All patients had D2 lymph node dissection. In 6 of
the 19 patients, the portal vein involved in the biliary
tract cancer was resected circularly and reconstructed
in end-to-end fashion. Intra-arterial adjuvant che-
motherapy was selectively performed for 9 patients
who consented to our proposal. Patients who had
chronic hepatitis, arterial anomaly and postoperative
stenosis of the hepatic artery were excluded. The
control group who underwent resection without adju-
vant chemotherapy comprised 10 patients. Age, gen-
der, staging of the disease (according to the latest
version of the Japanese Classification of Biliary Tract
Carcinoma), resection of the portal vein, presence of
histological liver invasion, postoperative radiotherapy
as demographics and clinical characteristics were
compared between the two groups.
Statistical analysis
Continuous variables were reported as the mean9
standard deviation and compared using the Mann-
Witney U-test. Categorical variables were compared
using the Fisher test. A two-sided p-value B0.05 was
considered statistically significant.
Intra-arterial adjuvant chemotherapy (in the
proper hepatic artery)
Using the Seldinger technique, the catheter was placed
in the proper hepatic artery via the right femoral artery
4 weeks after surgery. The catheter was connected to
the arterial infuser port, which was buried underneath
the skin in the right femoral region. Intra-arterial
infusion chemotherapy was started soon afterwards.
The protocol of the chemotherapy was as follows:
intra-arterial bolus injection of CDDP 10 mg/body
and continuous intra-arterial infusion of 5-FU
Table I. Clinicopathological features in patients of biliary tract cancer who underwent the radical operation between October 2001 and
September 2006 (Chemotherapy group).
Patient No. Gender Age Location Operation T N PV-resection Stage
1 female 76 Ampulla of Vater PPPD 3 0 yes III
2 female 69 Extrahepatic bile duct PPPD 3 0 no III
3 male 54 Extrahepatic bile duct SSPPD,lt hemi-hepatectomy 4 1 yes IVa
4 female 53 Gallbladder dorsal-sectoriectomy SSPPD,
rt hemi-hepatectomy
4 3 yes IVb
5 female 69 Gallbladder SSPPD, rt hemi-hepatectomy 4 3 yes IVb
6 male 61 Gallbladder Extended rt hemi-hepatectomy
dorsal-sectoriectomy
4 0 no IVa
7 female 55 Extrahepatic bile duct
(hilar lesion)
lt hemi-hepatectomy dorsal-sectoriectomy 3 2 no IVa
8 female 78 Gallbladder Combined resection of segments
(S4a,S5), resection of extrahepatic bile duct
4 1 yes IVa
9 male 80 Gallbladder Combined resection of segments
(S4a,S5), resection of extrahepatic bile duct
2 3 no III
Table II. Clinicopathological features in patients of biliary tract cancer who underwent the radical operation between October 2001 and
September 2006 (Control group).
Patient No. Gender Age Location Operation T N PV-resection Stage
10 female 75 Ampulla of Vater SSPPD 3 1 no III
11 female 73 Extrahepatic bile duct PPPD 2 1 no III
12 male 54 Ampulla of Vater SSPPD 3 0 no III
13 female 77 Extrahepatic bile duct SSPPD 3 0 no III
14 male 64 Extrahepatic bile duct PPPD 3 1 no III
15 male 61 Extrahepatic bile duct SSPPD 4 1 no IVa
16 male 49 Gallbladder Combined resection of segments (S4a,S5),
SSPPD
3 1 no III
17 female 45 Gallbladder Combined resection of segments (S4a,S5),
SSPPD resection of extrahepatic bile duct
4 1 no IVa
18 female 78 Gallbladder Combined resection of segments (S4a,S5),
resection of extrahepatic bile duct
4 2 no IVa
19 male 68 Extrahepatic bile duct
(hilar lesion)
lt hemi-hepatectomy dorsal-sectoriectomy 4 0 no IVa
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500 mg/body for 180 min. We repeated this menu
weekly as much as possible throughout the outpatient
department.
Results
Toxicity
There were no local side effects at the site of the
arterial infuser port. During the treatment, we ob-
served liver abscess (grade 3 according to Common
Terminology/Criteria for Adverse Events (CTCAE))
and anorexia (grades 1 and 2 (CTCAE)) in two
patients and bone marrow suppression (grade 1
(CTCAE)) in one.
Demographics and clinical characteristics
Demographics and clinical characteristics were similar
between the two groups, except for resection of the
portal vein (Table III). The chemotherapy group had
significantly more patients with resection of the portal
vein compared to the control group. Liver metastasis
occurred in 4 of 9 patients (44%) in the chemotherapy
group and in 5 of 10 (50%) in the control group
(Table IV). There was no difference statistically
between the two groups. In the chemotherapy group,
4 of 9 patients died from liver metastasis and 2 of 9
patients from peritoneal seeding. In the control group,
5 of 10 patients died from liver metastasis and 1 of 10
patients from peritoneal seeding. The causes of death
were statistically similar in the two groups (Table V).
Survival
Using Kaplan-Meier regression analysis, the median
survival term was 23.3 months for 9 patients who
underwent intra-arterial adjuvant chemotherapy
following curative operation and 21.7 months for
10 patients who were curatively resected without
the intra-arterial adjuvant chemotherapy. The differ-
ence in cumulative survival rate between the two
groups was not statistically significant (Figure 1).
In the recurrence-free survival, there was no signifi-
cant difference statistically between the chemoth-
erapy and control groups (the chemotherapy group,
17.2 months and the control group, 19.2 months)
(Figure 2).
Discussion
Biliary tract cancer is highly associated with a dismal
prognosis and with a 1-year survival rate of 25% [2].
Surgical resection or liver transplantation remains the
only curative treatment for biliary tract cancer. How-
ever, most patients are candidates for palliative
chemotherapy at an initial presentation, because
definitive diagnosis is often delayed until most lesions
are at an advanced stage [36].
Systemic chemotherapy for unresectable biliary
tract cancer can improve the quantity and quality of
life in those patients [7]. A regimen of 5-FU and
platin analogue is effective with response rates ranging
from 21% to 40%.
The combination of epirubicin, cisplatin, and con-
tinuous infusion of 5-FU is often administered in
patients with unresectable biliary tract cancer [8].
Gemcitabine or paclitaxel, new drugs, have demon-
strated response rates ranging from 0% to 16%, with a
median survival term of approximately 6 months [9].
If we could perform radical operations on patients
with advanced biliary tract cancer, most would be
guaranteed approximately only 2 years as the median
survival term, since local recurrence and distant
metastasis frequently occur after radical operation
[10,11]. Moreover, many patients who have under-
gone a radical operation for advanced biliary tract
cancer have died from liver metastasis.
Table III. Demographics and clinical characteristics in chemotherapy group and control group.
Chemotherapy group (n9) Control group (n10) P Value
Age 61.1910.7 66.3911.3 0.5
Gender M: F3: 6 M: F5: 5 0.9
Staging(JCS) Stage III: Stage IV3:6 Stage III: Stage IV6:4 0.2
Resection of portal vein :5:4 :1:9 0.03
Postoperative radiation :3:6 :2:8 0.5
Histological liver invasion :4:5 :3:7 0.5
Table IV. Comparison of the rate of liver metastasis between
chemotherapy group and control group.
Chemotherapy
group (n9)
Control group
(n10) P Value
Liver metastasis 4 (44%) 5 (50%) 0.8
Table V. Comparison of the cause of death between chemotherapy
group and control group.
Chemotherapy
group (n9)
Control group
(n10) P Value
Number of death 6 6
Cause of death
Liver metastasis 4 (66%) 5 (83%)
Peritoneal seeding 2 1 0.5
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In improving the prognosis of patients who undergo
radical surgery for biliary tract cancer, prevention of
liver metastasis is thought to be important. Adminis-
tering the anticancer drug directly into the hepatic
artery, which supplies blood to the bile duct and
gallbladder, has the potential to increase anticancer
agent concentration in the cancerous tissue and lead
to improved tumor killing in the liver [1214].
Sullivan et al. may have shown the first instance of
recanalization of a completely obstructed common
hepatic duct following hepatic arterial infusion of
floxuridine [15]. With hepatic arterial infusion of
anticancer drugs, they have a high hepatic extraction
after the first pass, and can reach bile canaliculi at
high concentration with minimal systemic toxicity.
Administration of cisplatin through the hepatic artery
provides a high concentration in blood perfusion,
whereas the systemic concentration of cisplatin is low
[16].
In our study, no grade 4 toxicity was observed; liver
metastasis occurred in 4 of 9 patients (44%) in the
chemotherapy group and in 5 of 10 patients (50%) in
the control group. Intra-arterial adjuvant chemother-
apy could not suppress the rate of liver metastasis.
Furthermore, the median survival term was 23.3
months for 9 patients who underwent the intra-arterial
adjuvant chemotherapy after surgery. On the contrary,
the median survival term was 21.7 months for 10
patients who were curatively resected without the intra-
arterial adjuvant chemotherapy. The cumulative sur-
vival rate was not improved by the intra-arterial
adjuvant chemotherapy. In conclusion, intra-arterial
adjuvant chemotherapy for biliary tract cancer is not
enough to suppress liver metastasis nor afford long-
term survival to patients.
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Figure 1. Overall survival rate between the chemotherapy and
control groups (Kaplan-Meier estimates).
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Figure 2. The disease-free survival rate between the chemotherapy
and control groups (Kaplan-Meier estimates).
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